Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma

Cancer Cell

Volumn 22, Issue 4, 2012, Pages 547-560

  Caro, Pilar ^a   Kishan, Amar U ^a,b   Norberg, Erik ^a,c   Stanley, Illana A ^a,c   Chapuy, Bjoern ^a   Ficarro, Scott B ^a,c   Polak, Klaudia ^a   Tondera, Daniel ^a   Gounarides, John ^d   Yin, Hong ^d   Zhou, Feng ^a,c   Green, Michael R ^a   Chen, Linfeng ^a   Monti, Stefano ^e,f   Marto, Jarrod A ^a,c   Shipp, Margaret A ^a   Danial, Nika N ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CARBON; GLUTATHIONE;

ARTICLE; CANCER SURVIVAL; CITRIC ACID CYCLE; CONTROLLED STUDY; FATTY ACID OXIDATION; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; NUTRIENT; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 84867595989     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.08.014     Document Type: Article

References (45)

1. Abramson J.S., Shipp M.A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005, 106:1164-1174.
2. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
3. Barger J.F., Plas D.R. Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. Endocr. Relat. Cancer 2010, 17:R287-R304.
4. Burton J.D., Goldenberg D.M., Blumenthal R.D. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res. 2008, 2008:494161.
5. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
6. Chen L., Monti S., Juszczynski P., Daley J., Chen W., Witzig T.E., Habermann T.M., Kutok J.L., Shipp M.A. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111:2230-2237.
7. Choe L., D'Ascenzo M., Relkin N.R., Pappin D., Ross P., Williamson B., Guertin S., Pribil P., Lee K.H. 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 2007, 7:3651-3660.
8. Compagno M., Lim W.K., Grunn A., Nandula S.V., Brahmachary M., Shen Q., Bertoni F., Ponzoni M., Scandurra M., Califano A., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
9. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
10. Dawson-Saunders B., Trapp R. Basic and Clinical Biostatistics 1994, Appleton & Lange, Norwalk, CT.
11. DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., Thompson C.B. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. USA 2007, 104:19345-19350.
12. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
13. Doughty C.A., Bleiman B.F., Wagner D.J., Dufort F.J., Mataraza J.M., Roberts M.F., Chiles T.C. Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Blood 2006, 107:4458-4465.
14. El-Aleem S.A., Schulz H. Evaluation of inhibitors of fatty acid oxidation in rat myocytes. Biochem. Pharmacol. 1987, 36:4307-4312.
15. Fan T.W., Lane A.N., Higashi R.M., Farag M.A., Gao H., Bousamra M., Miller D.M. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 2009, 8:41.
16. Garcia-Bates T.M., Baglole C.J., Bernard M.P., Murant T.I., Simpson-Haidaris P.J., Phipps R.P. Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation. J. Immunol. 2009, 183:6903-6912.
17. Guppy M., Leedman P., Zu X., Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem. J. 2002, 364:309-315.
18. Hsiao G., Chapman J., Ofrecio J.M., Wilkes J., Resnik J.L., Thapar D., Subramaniam S., Sears D.D. Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats. Am. J. Physiol. Endocrinol. Metab. 2011, 300:E164-E174.
19. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
20. Korge P., Weiss J.N. Redox regulation of endogenous substrate oxidation by cardiac mitochondria. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1436-H1445.
21. Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer 2005, 5:251-262.
22. Le A., Lane A.N., Hamaker M., Bose S., Gouw A., Barbi J., Tsukamoto T., Rojas C.J., Slusher B.S., Zhang H., et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012, 15:110-121.
23. Lee G., Elwood F., McNally J., Weiszmann J., Lindstrom M., Amaral K., Nakamura M., Miao S., Cao P., Learned R.M., et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J. Biol. Chem. 2002, 277:19649-19657.
24. Leesnitzer L.M., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., Davis R.G., Hull-Ryde E.A., Lenhard J.M., Patel L., et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002, 41:6640-6650.
25. Lenz G., Staudt L.M. Aggressive lymphomas. N. Engl. J. Med. 2010, 362:1417-1429.
26. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., Xu W., Tan B., Goldschmidt N., Iqbal J., et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 2008, 359:2313-2323. Lymphoma/Leukemia Molecular Profiling Project.
27. Marin-Valencia I., Yang C., Mashimo T., Cho S., Baek H., Yang X.L., Rajagopalan K.N., Maddie M., Vemireddy V., Zhao Z., et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012, 15:827-837.
28. McGarry J.D., Brown N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 1997, 244:1-14.
29. Monti S., Chapuy B., Takeyama K., Rodig S., Hao Y., Yeda K., Inguilizian H., Mermel C., Curie T., Dogan A., et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B-cell lymphoma. Cancer Cell 2012, 22:359-372.
30. Monti S., Savage K.J., Kutok J.L., Feuerhake F., Kurtin P., Mihm M., Wu B., Pasqualucci L., Neuberg D., Aguiar R.C., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105:1851-1861.
31. Moreno-Sánchez R., Rodríguez-Enríquez S., Saavedra E., Marín-Hernández A., Gallardo-Pérez J.C. The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells?. Biofactors 2009, 35:209-225.
32. Morrish F., Neretti N., Sedivy J.M., Hockenbery D.M. The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 2008, 7:1054-1066.
33. Ookhtens M., Baker N. Fatty acid oxidation to H2O by Ehrlich ascites carcinoma in mice. Cancer Res. 1979, 39:973-980.
34. Ookhtens M., Kannan R., Lyon I., Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am. J. Physiol. 1984, 247:R146-R153.
35. Pike L.S., Smift A.L., Croteau N.J., Ferrick D.A., Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 2011, 1807:726-734.
36. Polo J.M., Juszczynski P., Monti S., Cerchietti L., Ye K., Greally J.M., Shipp M., Melnick A. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc. Natl. Acad. Sci. USA 2007, 104:3207-3212.
37. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., Khainovski N., Pillai S., Dey S., Daniels S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3:1154-1169.
38. Rossignol R., Gilkerson R., Aggeler R., Yamagata K., Remington S.J., Capaldi R.A. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. 2004, 64:985-993.
39. Samudio I., Harmancey R., Fiegl M., Kantarjian H., Konopleva M., Korchin B., Kaluarachchi K., Bornmann W., Duvvuri S., Taegtmeyer H., Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 2010, 120:142-156.
40. Schafer Z.T., Grassian A.R., Song L., Jiang Z., Gerhart-Hines Z., Irie H.Y., Gao S., Puigserver P., Brugge J.S. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009, 461:109-113.
41. Tennant D.A., Durán R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 2010, 10:267-277.
42. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
43. Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 2003, 100:9991-9996.
44. Yuneva M.O., Fan T.W., Allen T.D., Higashi R.M., Ferraris D.V., Tsukamoto T., Matés J.M., Alonso F.J., Wang C., Seo Y., et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012, 15:157-170.
45. Zaugg K., Yao Y., Reilly P.T., Kannan K., Kiarash R., Mason J., Huang P., Sawyer S.K., Fuerth B., Faubert B., et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011, 25:1041-1051.